Evolent Health Inc. (NYSE:EVH) has a beta of 2.37. The stock’s Relative Strength Index (RSI) is 55.15, with weekly volatility at 2.83% and ATR at 0.66. The EVH stock’s 52-week price range has touched low of $3.50 and a $20.20 high. Its shares traded lower over the last trading session, losing -1.10% on 02/18/21. The shares fell to a low of $18.69 before closing at $18.87. Intraday shares traded counted 0.36 million, which was 35.2% higher than its 30-day average trading volume of 550.03K. EVH’s previous close was $19.08 while the outstanding shares total 85.17M.
Investors have identified the Health Information Services company Evolent Health Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.64 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Evolent Health Inc. (EVH) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 548.54 million total, with 365.5 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.45 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on EVH sounds very interesting.
Is the stock of EVH attractive?
In related news, General Counsel, Weinberg Jonathan sold 10,000 shares of the company’s stock in a transaction that recorded on Aug 05. The sale was performed at an average price of 13.01, for a total value of 130,100. In the last 6 months, insiders have changed their ownership in shares of company stock by 9.02%.
6 out of 9 analysts covering the stock have rated it a Buy, while 3 have maintained a Hold recommendation on Evolent Health Inc.. 0 analysts has assigned a Sell rating on the EVH stock. The 12-month mean consensus price target for the company’s shares has been set at $18.43.